Start Tour
presents
Anti-TNF factors reduce
intestinal inflammation
Sinus infections and sore throats are examples
of respiratory infections someone might experience while taking a biologic. They are possible side effects of infliximab, certolizumab pegol, and adalimumab.
Infliximab can also cause other respiratory symptoms, such as coughing.
Respiratory infection side effects
Surgery for
ulcerative colitis
Treatment guide:
Integrin receptor agonists
keep cells in blood vessels
Anti-TNF biologics, such as infliximab, adalimumab, and certolizumab pegol, help
with Crohn’s symptoms in the gut by reducing inflammation in the intestines and other tissues. TNF orchestrates the inflammatory immune response. Stopping TNF reduces this
inflammatory immune response.
The result is that people with Crohn’s might experience reduced inflammation throughout
the body, specifically in the gut.
Integrin receptor agonists, such as natalizumab and vedolizumab, stop inflammatory cells from leaving blood vessels so they do not enter tissues. These medications stop inflammatory cells from moving to the intestinal lining.
The first doses of biologics are usually via intravenous (IV) infusion. This takes place
at a healthcare facility where a healthcare professional inserts a needle into a vein in the arm. All biologics can cause reactions on the skin at the injection site, including swelling, itching, pain, bruising, or rash.
Injections can cause skin reactions
Many biologics can cause an ill feeling
in the stomach.
Infliximab and natalizumab can cause pain,
while adalimumab is one biologic that can
cause nausea. Certolizumab pegol can cause weight gain.
Nausea, stomach pain,
and weight gain are possible
Some biologics can cause side effects in the urinary tract or the genital area.
Ustekinumab can cause vaginal yeast infections
or urinary tract infections (UTIs). Natalizumab and certolizumab pegol can also cause UTIs.
Urinary tract or yeast
infections might happen
est. read time: 6 min
Biologics for Crohn's disease
Treatment guide:
XXxxxxxxx xxxxxxxxxx
Treatment guide:
pg 2
pg 1
Interleukin-12/23 antagonists target
interleukin-12 and interleukin-23, proteins that cause inflammation in the gut. Options include:
pg 2
Integrin receptor agonists, such as natalizumab and vedolizumab, stop inflammatory cells from leaving blood vessels so they do not enter tissues. These medications stop inflammatory cells from moving to the intestinal lining.
pg 1
Integrin receptor agonists
keep cells in blood vessels
